AVTR

14.8401.85%
ME

Michael E. Severino

CEO & Director

Dr. Michael E. Severino, also known as Mike, M.D., is Chief Executive Officer and Director of Sarepta Therapeutics, Inc. from July 28, 2026. He is Director at Quotient Therapeutics. He serves as an Independent Director at Viatris Inc. from May 5, 2025. Dr. Severino serves as Director of Montai Health, Inc. since May 2023. He has been an Independent Director at Avantor, Inc. since April 22, 2020. Dr. Severino served as the Chief Executive Officer and Director at Tessera Therapeutics, Inc. from June 2022 until July 2026. He joined Tessera Therapeutics, Inc. in June 2022. He serves as Director of Tessera since 2022. He serves as CEO-Partner at Flagship Pioneering Inc. He joined Flagship Pioneering Inc in 2022. Dr. Severino had been a Vice Chairman and President at AbbVie Inc. since December 17, 2018 until May 31, 2022. Dr. Severino has extensive experience in research and development and corporate strategy for leading companies focused on developing life-saving therapies for patients, along with his independence. He served as a Chief Scientific Officer and Executive Vice President of Research & Development at AbbVie Inc. since May 15, 2014 until December 17, 2018, where he led efforts to build a strong pipeline and advance promising science for patients in the areas of hematologic oncology, immunology and neuroscience. He joined AbbVie Inc. in 2014 and was first appointed as an AbbVie Inc. Corporate Officer in June 2014. Dr. Severino served as a Senior Vice President of Global Development and Corporate Chief Medical Officer at Amgen Inc. since February 14, 2012 until 2014. He served as the Vice President of Global Development at Amgen. Dr. Severino joined Amgen as Senior Director of Inflammation Early Development. He held the role of Head of Amgen's Proof-of-Concept group within Medical Sciences, where he was responsible for leading a team of physician-scientists responsible for Amgen's late pre-clinical and early clinical programs across all therapeutic areas. In 2006, he assumed leadership of the Inflammation Therapeutic Area in Global Clinical Development and served as its Vice President of Global Development since 2007. Prior to joining Amgen, he held positions of increasing responsibility at Merck Research Laboratories across a wide range of therapeutic areas including Vaccines/Infectious Diseases, Oncology, Diabetes/Metabolic Disorders and Neurosciences. Dr. Severino serves on the Board of Directors for the Field Museum in Chicago, Illinois. He was a Member of the Phi Beta Kappa Society. He was a Member of the Alpha Omega Alpha Honor Medical Society. He completed his residency and fellowship training in Internal Medicine and Infectious Diseases at Massachusetts General Hospital and Harvard Medical School. Dr. Severino also brings Healthcare Industry Experience to the Board. Dr. Severino holds a B.S. in biochemistry from the University of Maryland. Dr. Severino holds a Doctor of Medicine from The Johns Hopkins University.

Positions